The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
Picot J, Cooper K, Bryant J, Clegg AJ
Record ID 32011000751
English
Authors' objectives:
To assess the clinical effectiveness and cost-effectiveness of bortezomib or thalidomide in combination chemotherapy regimens with an alkylating agent and a corticosteroid for the first-line treatment of MM.
Authors' recommendations:
Service provision is unlikely to change greatly; however, uncertainties remain and further research is needed. In particular, head-to-head trials of bortezomib- and thalidomide-containing combination regimens are desirable. These trials should include assessments of patient HRQoL in response to treatment. It is not known whether the choice of second-line treatment or the sequence of treatments affects patient outcomes.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hta.ac.uk/2049
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Boronic Acids
- Multiple Myeloma
- Pyrazines
- Thalidomide
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
<p>2011 Queen's Printer and Controller of HMSO</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.